Binimetinib (Standard)

• Description :

  Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.

• CAS Number :

  [606143-89-9]

• Product Name Alternative :

  MEK162 (Standard) ; ARRY-162 (Standard) ; ARRY-438162 (Standard)

• UNSPSC :

  12352005

• Hazard Statement :

  H411

• Target :

  Autophagy; MEK; Reference Standards

• Type :

  Reference Standards

• Related Pathways :

  Autophagy; MAPK/ERK Pathway; Others

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/binimetinib-standard.html

• Smiles :

  BrC1=CC=C(C(F)=C1)NC2=C(C3=C(C=C2C(NOCCO)=O)N(C=N3)C)F

• Molecular Formula :

  C17H15BrF2N4O3

• Molecular Weight :

  441.23

• Precautions :

  P273-P391-P501

• References & Citations :

  [1]J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794.|[2]Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123 (6), 2551-2563.|[3]Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6 (39) :42183-96.|[4]Cheng H, et al. PIK3CA (H1047R) - and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35 (23) :2961-70.|[5]Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7 (15) :19997-20015.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference Standards